Adarx jumps 30% After $446M Upsized IPO
Summary
Adarx, a late-stage developer of gene therapies, saw its shares surge by 30% following a successful upsized initial public offering that raised $446.3 million. This strong performance comes amid a vibrant market for biotech IPOs in 2026, which has shown resilience and a steady pace of new listings despite broader market challenges. Additionally, Adarx has a multi-year strategic partnership with AbbVie, which provides both upfront payments and opportunities for advancing siRNA candidates in various therapeutic areas.
Analysis
Adarx: ADARx Pharmaceuticals is a San Diego-based clinical-stage biotechnology company focused on developing next-generation siRNA therapeutics that regulate gene expression to treat diseases affecting the immune, kidney, cardiovascular, and neurological systems. Its pipeline includes wholly-owned candidates targeting complement-mediated diseases, hereditary angioedema, and thrombotic conditions, with additional programs in obesity and neurodegenerative diseases. The company recently completed an upsized Nasdaq IPO amid strong investor interest in the biotech sector and maintains an ongoing collaboration with AbbVie on its RNA-silencing platform. Biotech IPO Momentum: Biotech has stood out as a resilient segment in the 2026 IPO market, sustaining a steady pace of new listings into the fall despite broader market selectivity. Strategic Collaboration: ADARx maintains a multi-year strategic partnership with AbbVie that includes upfront payments and options for advancing siRNA candidates across therapeutic areas.
Categories
macro
Related sources
- https://www.renaissancecapital.com/IPO-Center/News/121878/sirna-biotech-adarx-pharmaceuticals-prices-upsized-ipo-at-17-the-high-end
- https://endpoints.news/adarx-targets-319m-ipo-as-trexbio-retension-join-filing-queue/
- https://www.bloomberg.com/news/articles/2026-09-24/adarx-pharmaceuticals-raises-446-3-million-in-upsized-us-ipo
- https://www.bloomberg.com/news/articles/2026-09-04/adarx-pharmaceuticals-files-for-us-ipo-to-fund-rna-treatment
- https://markets.businessinsider.com/news/stocks/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering-1036572946
- https://www.lw.com/en/news/2026/09/latham-advises-on-adarx-pharmaceuticals-upsized-initial-public-offering
- https://www.bloomberg.com/news/articles/2026-09-21/drugmaker-adarx-pharma-seeks-to-raise-371-9-million-in-us-ipo
- https://www.ifre.com/equities/2490467/adarx-prices-upsized-nasdaq-ipo-at-top
- https://finimize.com/content/biotech-ipos-keep-coming-and-adarx-led-the-week
- https://www.sec.gov/Archives/edgar/data/1802369/000119312526396007/0001193125-26-396007.txt
- https://bloomberg.com/authors/AVmRj2dywwc/angel-adegbesan
- https://www.bloomberg.com/news/articles/2026-09-25/adarx-pharma-shares-climb-30-after-446-3-million-upsized-ipo
- https://www.reuters.com/legal/litigation/adarx-pharmaceuticals-raises-4463-million-upsized-us-ipo-2026-09-25/
- https://www.biopharmadive.com/news/adarx-rnai-biotech-ipo-stock-pricing/831262/
- https://www.tradingview.com/news/DJN_DN20260925002902:0/
- http://rmb.reuters.com/rmd/rss/item/tag:reuters.com,2026:newsml_KBN3VB11U?channel=frL012